Price
chg
chg neg
quotes and stock data may be delayed 15 minutes
My Notes
Only BPIQ Pro members can create company notes. Learn more here.
52 wk low
low api
52 wk hi
high api
Cash
$41.3M
Burn Rate (Qtr)
$8.0M
Mkt Cap
mkt cap api
Avg Volume
volume api
*cash/burn updated:
Q1 '22
Drug Pipeline
Click the button to see the updated pipeline
No drug found
We don't have any drug data for this company yet
Drug | Disease (links)
Stage (next event)
Catalyst Date
Loading Catalysts...
search in progress
Pipeline powered by
IMNN
Company Profile
(Formerly Celsion Corporation; NASDAQ CLSN)
Imunon, a clinical-stage biotechnology company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and vaccines. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for the treatment of primary liver cancer. The company is also developing GEN-1, a DNA-based immunotherapeutic product, which is in Phase II clinical trials for the localized treatment of ovarian cancers.
Recent Posts
See what the community is saying - click to see full post.